Definitive collection of precision medicine technology and diagnostic solutions

AVENIO ctDNA Expanded Kits (Roche)

The AVENIO ctDNA Expanded Kit is a next-generation sequencing (NGS) liquid biopsy tumor profiling assay for identifying genomic aberrations derived from solid tumors. This panel contains 77 genes, including those currently in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1 This panel also contains emerging biomarkers relevant to clinical research.


Roche Sequencing and Life Science

9115 Hague Road
Indianapolis, IN 46256
855-527-2246
https://sequencing.roche.com/en-us.html

Learn more about this product

REQUEST INFO: AVENIO ctDNA Expanded Kits (Roche)

Benefits

    • Confidently report all four mutation classes – SNVs, indels, fusions, and CNVs—from just 10 – 50 ng of cfDNA.
    • Delivers exceptional analytical performance supported by integrated digital error suppression (iDES) strategies, combining molecular barcodes with in silico error suppression techniques.2,3
    • Analyze plasma containing DNA from a variety of solid tumor types using a single workflow optimized for running up to 16 samples at a time.
    • Rely on a single trusted supplier for complete support of your isolations, library prep, target enrichment panels, and post-hybridization reagents.
    • Receive an inclusive solution with the required reagents, a robust bioinformatics pipeline, and software for analysis and reporting to keep your lab at the forefront of cancer research.

Research focus

  • Lung, Colorectal, Breast, Gastric, Prostate, Glioma, Melanoma, Ovarian, Thyroid, and Pancreatic

Applications

  • Non-invasive tumor profiling
  • Non-invasive detection of resistance biomarkers
  • Investigation of emerging cancer biomarkers
1.  National Comprehensive Cancer Network. http://www.nccn.org. October 15, 2016.
2.  Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016;34(5):547–555. doi:10.1038/nbt.3520.
3.  Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554. doi:10.1038/nm.3519.
†   Required hardware: Illumina NextSeq 500/550 sequencer and Roche Oncology Analysis Server. NextSeq 500/550 instruments and associated sequencing reagents are manufactured and sold by lllumina and are not supplied by Roche

For Research Use Only. Not for use in diagnostic procedures.
AVENIO is a trademark of Roche. NEXTSEQ is a trademark of Illumina. All other product names and trademarks are the property of their respective owners.
© 2020 Roche Sequencing & Life Science. All rights reserved.

Posters & Papers

Webinars & Videos

AVENIO ctDNA Expanded Kits from Roche

AVENIO ctDNA Expanded Kits (Roche)

Scroll Up